LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial

Autor:	Andrés Redondo, J. Løhndorf, Fabian Trillsch, R. dePont Christensen, M. Gil-Martin, Beyhan Ataseven, F Marmé, M.P. Barretina Ginesta, M. J. Rubio, Annika Auranen, Bente Lund, Kristina Lindemann, Mansoor Raza Mirza, H. Roed, G-B. Nyvang, Jalid Sehouli, IB Runnebaum, Vanda Salutari, Line Bjørge
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty business.industry Letrozole Hematology Palbociclib Placebo Recurrent Endometrial Cancer Double blind Internal medicine medicine In patient Oestrogen receptor business medicine.drug
Zdroj:	Annals of Oncology. 31:S1160
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.2258
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::37ec57ee39a6678b02f76cc0fa3a5fa7 https://doi.org/10.1016/j.annonc.2020.08.2258 Zobrazit plný text záznamu